- Home
- ATYR vs PSNL Comparison
ATYR vs PSNL Comparison
Compare ATYR & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- PSNL
- Stock Information
- Founded
- ATYR 2005
- PSNL 2011
- Country
- ATYR United States
- PSNL United States
- Employees
- ATYR N/A
- PSNL 229
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- PSNL Medical Specialities
- Sector
- ATYR Health Care
- PSNL Health Care
- Exchange
- ATYR Nasdaq
- PSNL Nasdaq
- Market Cap
- ATYR 535.0M
- PSNL 478.0M
- IPO Year
- ATYR 2015
- PSNL 2019
- Fundamental
- Price
- ATYR $5.63
- PSNL $5.80
- Analyst Decision
- ATYR Strong Buy
- PSNL Strong Buy
- Analyst Count
- ATYR 5
- PSNL 4
- Target Price
- ATYR $23.25
- PSNL $8.13
- AVG Volume (30 Days)
- ATYR 4.3M
- PSNL 844.2K
- Earning Date
- ATYR 11-06-2025
- PSNL 11-05-2025
- Dividend Yield
- ATYR N/A
- PSNL N/A
- EPS Growth
- ATYR N/A
- PSNL N/A
- EPS
- ATYR N/A
- PSNL N/A
- Revenue
- ATYR N/A
- PSNL $80,317,000.00
- Revenue This Year
- ATYR $478.72
- PSNL N/A
- Revenue Next Year
- ATYR $1,899.26
- PSNL $29.83
- P/E Ratio
- ATYR N/A
- PSNL N/A
- Revenue Growth
- ATYR N/A
- PSNL 0.36
- 52 Week Low
- ATYR $1.67
- PSNL $2.83
- 52 Week High
- ATYR $7.29
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- ATYR 58.33
- PSNL 61.83
- Support Level
- ATYR $5.08
- PSNL $4.73
- Resistance Level
- ATYR $5.77
- PSNL $6.26
- Average True Range (ATR)
- ATYR 0.42
- PSNL 0.28
- MACD
- ATYR 0.02
- PSNL 0.16
- Stochastic Oscillator
- ATYR 66.67
- PSNL 71.62
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.